Bank of America moved International Flavors & Fragrances to Underperform from Buy, a two-notch cut that landed on November 6 and trimmed the bank’s price target on the New York-listed ingredients group to $91 from $95. The BofA IFF downgrade rests less on a single weak quarter than on the idea that the stock has already traveled far enough to make the next leg harder to find.
At the heart of the call is a simple observation: IFF shares have climbed substantially, and the bank sees few near-term events capable of pushing them meaningfully higher. BofA also flagged softness in parts of the portfolio outside Taste, the segment that has been carrying the company’s growth story.
A Strong Quarter That Still Fell Short of the Bar
IFF’s third-quarter numbers themselves were solid. Net sales reached $1.94 billion, a 4% increase, and adjusted operating EBITDA came in at $403 million, ahead of BofA’s own $398 million estimate. The company also lifted the low end of its 2026 sales guidance, putting the range at $7.5 billion to $7.6 billion.
But the details mattered as much as the headline figures. Health & Biosciences, one of IFF’s three reporting segments, expanded by just 1%, the weakest pace among the group. That contrast helps explain why BofA described the quarter as strong while still concluding that the risk/reward profile had shifted.
Margin Pressure Builds Into 2027
The bank’s caution extends beyond the top line. BofA expects raw material inflation of roughly 3% to constrain operating leverage through the first half of 2027, a period in which cost increases may be difficult to fully offset. That view underpins the downgrade even as sales trends remain positive.
For investors, the tension is straightforward: IFF is still growing, but the pace of margin expansion may lag what the share price already implies. BofA’s price target reduction, though modest at $4, signals a lower ceiling rather than a collapse in the business.
Portfolio Moves and Buyback Completion
IFF is not standing still on the corporate front. The company is in the process of selling its Food Ingredients business, a transaction expected to close by the end of the second quarter of 2027. It has also finished its $500 million share repurchase authorization, a step that removes one source of support from the equity story.
Those moves fit a broader reshaping of the portfolio, though BofA’s note suggests they are not enough on their own to change the near-term trajectory of the stock.
What the Downgrade Means for the Stock
IFF carries a market capitalization of $20.69 billion, and analysts’ average price target implies upside potential of about 19%. The company had 39 hedge fund holders in the second quarter of 2026, according to the report.
The downgrade arrived during a turbulent week for equities more broadly, with major indexes falling sharply and chipmakers and AI-linked names absorbing the heaviest losses. IFF’s own story, however, is tied to ingredients, pricing and segment mix rather than the data-center trade that drove the wider selloff.
BofA’s view now sits at the more cautious end of the analyst spectrum. The bank’s argument is not that IFF is broken, but that the easy gains have been made, the catalysts are thin, and cost pressures are likely to keep a lid on operating leverage well into next year.